|
|
|
|
Vol. 55, Issue 1, 179-185, January 1999
Laboratory of Molecular and Developmental Neuroscience, Massachusetts General Hospital-East, Charlestown, Massachusetts
| |
Summary |
|---|
|
|
|---|
Glutamate carboxypeptidase II (GCP II) catalyzes the extracellular
hydrolysis of the neuromodulator
N-acetyl-aspartylglutamate to
N-acetyl-aspartate and glutamate. GCP II also hydrolyzes
-glutamyl bonds in folylpolyglutamate. The predicted amino acid
sequence of GCP II displays similarities to aminopeptidases from
Streptomyces griseus and Vibrio
proteolyticus, whose crystal structures have been determined.
These aminopeptidases are cocatalytic zinc metallopeptidases belonging
to the peptidase family M28. Specific zinc and substrate ligands have
been proposed in GCP II based on the amino acid sequence alignment to
these M28 family members. In the present study, site-directed mutagenesis has been used to test the assignment of these putative ligands in human GCP II. Substitutions to the five putative zinc ligands resulted in severely reduced enzyme activity, although mutant
protein was expressed as demonstrated by immunoblot analysis. In
addition, substitutions of amino acids near the putative zinc ligands
have identified other specific residues important for enzyme structure
and/or function. Substitutions to putative substrate ligands were less
perturbing, and increases in Km were
observed for substitutions that introduced a large charge perturbation (e.g., Lys to Glu). The results from substitutions at the proposed zinc
and substrate ligands are consistent with the assignment of these
residues and suggest that GCP II has a three-dimensional structure
similar to other members of the peptidase family M28.
| |
Introduction |
|---|
|
|
|---|
Glutamate
carboxypeptidase II (GCP II) hydrolyzes the abundant neuropeptide
N-acetyl-aspartylglutamate (NAAG) to
N-acetyl-aspartate and glutamate in the extracellular space
(Robinson et al., 1987
; Stauch et al., 1989
; Serval et al., 1990
;
Slusher et al., 1990
). NAAG inhibits glutamate's activation of the
N-methyl-D-aspartate ionotropic
receptor (Sekiguchi et al., 1989
; Puttfarcken et al., 1993
; Burlina et
al., 1994
; Grunze et al., 1996
) and is an agonist at the metabotropic
glutamate receptor mGluR3 (Wroblewska et al., 1997
). GCP II terminates
the action of NAAG and generates extrasynaptic glutamate in the brain.
Inhibition of GCP II by 2-(phosphonomethyl)pentanedioic acid (PMPA),
has been shown to be effective in preventing neuronal cell death in
models of ischemia (Harukuni et al., 1997
). GCP II also hydrolyzes
-glutamyl linkages in pteroylpolyglutamate (Pinto et al., 1996
).
Conversion of pteroylpolyglutamate to pteroylmono-glutamate is
necessary for intestinal absorption of folic acid.
GCP II is also expressed in selected sites outside the brain including
nonmyelinating Schwann cells and the neuromuscular junction, small
intestine, kidney, and prostate (Slusher et al., 1992
; Berger et al.,
1995a
,b
; Troyer et al., 1995a
). At some of these peripheral sites, GCP
II may act on substrates other than NAAG. The name glutamate
carboxypeptidase II (EC 3.4.17.21) has been recently assigned; the
enzyme has previously been called N-acetyl-
-linked acidic
dipeptidase or NAALADase and prostate-specific membrane antigen or PSM.
Molecular characterizations of rat, pig, and human forms of GCP II have
been described (Israeli et al., 1993
; Carter et al., 1996
; Bzdega et
al., 1997
; Halsted et al., 1998
; Luthi-Carter et al., 1998
).
GCP II is a class II membrane glycoprotein with an apparent molecular
mass of 94 to 100 kDa. Class II membrane proteins have a short
cytoplasmic amino terminus, a single membrane-spanning domain, and a
large extracellular domain (Fig. 1). A
model for human GCP II has recently been proposed by Rawlings and
Barrett (1997)
based on a region of similarity to the peptidase family M28 comprised of cocatalytic metallopeptidases. The catalytic domain of
GCP II (Fig. 1) has been identified by sequence similarities to low
molecular weight aminopeptidases from Streptomyces griseus and Vibrio proteolyticus (also known as Aeromonas
proteolytica). The X-ray crystal structures have been determined
for the Streptomyces and Vibrio aminopeptidases
at 1.75-Å and 1.8-Å resolution, respectively (Chevrier et al., 1994
;
Greenblatt et al., 1997
). These peptidases have a binuclear
Zn++ center at the active site in which the two
zinc ions share a bridging carboxylate ligand. In addition, the
structure of carboxypeptidase G2 has been
determined at 2.5-Å resolution and has a central topology quite
similar to the Vibrio aminopeptidase, even though no
significant amino acid sequence identity exists (Rowsell et al., 1997
).
Carboxypeptidase G2 hydrolyzes the
-linked
glutamate from folic acid. The binuclear zinc-binding sites found in
carboxypeptidase G2 and the Vibrio aminopeptidase are highly similar in structure and ligand environment (Table 1).
|
|
To test amino acid assignments, putative ligands for
Zn++ in GCP II have been targeted for amino acid
substitution based on the alignment of the amino acid sequence to the
Streptomyces and Vibrio aminopeptidases. The five
putative Zn++ ligands and their positions in GCP
II are: His-377, Asp-387, Glu-425, Asp-453, and His-553, where Asp-387
is predicted to be the bridging ligand (Table 1). In contrast to both
structural and catalytic mono-zinc sites, carboxylate oxygen
coordination predominates in binuclear zinc sites (Vallee and Auld,
1993
).
The crystal structure of the Vibrio aminopeptidase shows 10 residues lining a hydrophobic specificity pocket implicated in substrate binding (Chevrier et al., 1994
). In the amino acid sequence alignment, Rawlings and Barrett (1997)
noted that four of the residues
that line the specificity pocket of the Vibrio enzyme are
substituted by positively charged residues (i.e., Arg-463, Lys-499,
Arg-536, and Lys-545), which may account in part for substrate
specificity in GCP II (Table 2). These
and some of the other 10 predicted substrate ligands, a subset of which
are next to putative zinc ligands, have been targeted for amino acid substitution (Tables 1 and 2).
|
| |
Materials and Methods |
|---|
|
|
|---|
Site-Directed Mutagenesis.
The cDNA for human GCP II has
been subcloned into the mammalian expression vector, pcDNA3 (Invitrogen
Corporation, Carlsbad, CA). Single-stranded template was used in an in
vitro mutagenesis reaction according to Kunkel et al. (1991)
. When
possible, restriction sites were designed into or out of the mutation
site to facilitate screening. Mutations were confirmed by DNA sequencing.
Radioenzymatic Assay of Enzyme Activity.
To test for
alterations in function of the encoded proteins, plasmids containing
the confirmed mutations were transiently transfected into the prostate
cancer cell line PC3 (American Type Culture Collection, Rockville, MD),
which does not express endogenous GCP II activity or protein (Carter et
al., 1996
). Transfections were carried out following a calcium
phosphate method in 50 mM HEPES, pH 7.05 (Graham and van der Eb, 1973
).
After incubation for 48 h, cells were harvested at 4°C and
sonicated in the presence of 50 mM Tris, pH 7.4, 0.5% Triton X-100 in
high-pressure liquid chromatography grade H2O. Cell
lysates were then incubated in the presence of the radiolabeled
substrate
N-acetyl-L-aspartyl-L-[3,4-3H]glutamate
(NEN Life Science Products, Boston, MA). Products were separated from
intact substrate using disposable anion exchange columns and
L-[3,4-3H]glutamate measured by scintillation
spectrometry as described in a study by Robinson et al. (1987)
.
Enzymatic activity of GCP II in 2 µg of total protein from the cell
lysate was assayed in a final volume of 250 µl using 30 nM
N-acetyl-L-aspartyl-L-[3,4-3H]glutamate
in 50 mM Tris, pH 7.4, at 37°C, 0.1% Triton X-100, 150 µM
potassium phosphate, and 1 mM CoCl2 (Robinson et al.,
1987
). Total protein was assayed using the bicinchoninic acid assay
(Pierce, Rockford, IL). To test for metal ion dependence of mutant
enzyme activity, activity was recovered by the addition of
Co++ or Zn++ in the presence of EDTA (Robinson
et al., 1987
). Because all transfects were expressed in the same cell
system, it is assumed that differences in kinetic characteristics
reflect primarily the transfected species.
Kinetic Analysis. For those mutants that showed activity, Michaelis-Menten (saturation) kinetics were performed. The Km and Vmax parameters were determined by a nonlinear least-squares fit of the initial velocity versus substrate concentration plot using Prism software (GraphPad, San Diego, CA) where the error in these parameters is represented by the 95% confidence interval. At each substrate concentration, three time points were taken either at 15, 30, and 45 min for wild type or up to 120, 180, and 240 min for mutants within the linear range of the assay. Background counts from the coelution of intact substrate were subtracted from each point by including a sample without enzyme. The concentration of the labeled substrate [3H]NAAG was kept constant at 30 nM, whereas the concentration of unlabeled substrate was varied from 100 to 3000 nM. The initial velocity, v (in femtomoles per minute), at a given substrate concentration was determined from the slope of the linear plot of product versus time where the error in the initial velocity is represented by the S.E.M. of the 95% confidence interval from the linear regression of the slope. To compare changes in Vmax between mutant and wild-type enzymes, the Vmax parameter has been normalized by the ratio of wild-type to mutant protein from the relative intensity of the signal measured from an immunoblot (see below).
Inhibitor Analysis.
Activity of selected mutants was
measured in the presence of varying concentrations of inhibitors in a
volume of 125 µl using 2 µg of total protein, 1 mM
CoCl2, and 10 nM [3H]NAAG. PMPA was a gift
from Dr. Barbara Slusher (Guilford Pharmaceuticals, Baltimore, MD).
Pteroylpenta-
-glutamate was purchased from B. Schircks Laboratories
(Jona, Switzerland). [3H]NAAG is shipped in phosphate
buffer, however phosphate inhibition of GCP II did not interfere with
kinetic analysis at the concentration of [3H]NAAG used.
To exchange the buffer for inhibitor analysis and to purify
N-acetyl-L-aspartyl-L-[3,4-3H]glutamate
(NEN Life Science Products), up to 250 µl of 24 µM [3H]NAAG was applied to a 1-ml bed volume of anion
exchange resin AG 1-X8 (Bio-Rad, Hercules, CA), washed with 3 ml of 1 M
formic acid, and eluted in 3 ml of 7.5 M formic acid. The sample was lyophilized and resuspended in 3 ml of H2O and lyophilized
two more times. The pellet was resuspended in 200 mM Tris, pH 9.5, and
if necessary, the pH adjusted to 7.0 with NaOH.
Immunoblot Analysis.
To normalize for the amount of enzyme
used between wild type and mutants in the kinetic assays, the relative
amount of GCP II protein was quantitated by immunoblotting (Western
blot analysis). Cellular lysates were separated by 7%
SDS-polyacrylamide gel electrophoresis, transferred to nitrocellulose
in 10 mM 3-cyclohexylamino-1-propane sulfonic acid, pH 11, 1%
methanol, and probed with the monoclonal antibody 7E11-C5 at 3 µg/ml
(a generous gift from Drs. Gerald Murphy and Alton Boynton) (Israeli et
al., 1994
). The 7E11-C5 antibody recognizes the N terminus of GCP II
(Troyer et al., 1995b
). Because no mutations were near this epitope,
amino acid substitutions were not expected to interfere with binding of
the antibody. Horseradish peroxide-conjugated secondary antibody
(Jackson ImmunoResearch Laboratories, Inc., West Grove, PA) was used to
visualize the complex in conjunction with the chemiluminescent
substrate SuperSignal ULTRA (Pierce). Data were collected with a
Fluor-S MultiImager (Bio-Rad) and analyzed by Multi-Analyst software
(Bio-Rad). To test that the immunoblot was linear in the range of
experimental samples, the intensities were measured as a function of
time. The amount of GCP II protein is expressed per microgram of total protein loaded. For qualitative analysis, immunoblots were visualized using film autoradiography.
Deglycosylation of Native Protein. To characterize the two bands observed in the immunoblot of transiently expressed GCP II, samples were deglycosylated under denaturing conditions with peptide-N-glycosidase according to the manufacturer's recommended protocol (Oxford GlycoSciences, Inc., Bedford, MA) and probed with 7E11-C5 antibody in an immunoblot as described above.
| |
Results |
|---|
|
|
|---|
Substitutions to Putative Zinc Ligands.
Based on amino acid
sequence alignment to other cocatalytic zinc peptidases of the M28
family, the catalytic domain and potentially important functional
groups have been identified in GCP II (Rawlings and Barrett, 1997
).
Site-directed mutagenesis has been used to test the assignment of
specific amino acid residues implicated in zinc and substrate binding.
Single substitutions to putative zinc ligands resulted in a profound
loss of enzyme activity (Table 3). The
severe loss of activity in these mutants is not due to the inability of
transfectants to express GCP II protein, as determined by immunoblot
analysis (examples shown in Fig. 2A).
However, reduced expression was observed for some of these mutants
(Table 3). The only mutant in which kinetic parameters were obtainable
was D387N, a substitution at the putative bridging ligand that resulted in both an increased Km value and a
decreased Vmax when compared with wild type
(Fig. 3 and Table
4). The profile of activity versus metal
ion concentration did not change for the D387N and E424Q (see below)
mutants when compared with wild-type enzyme, suggesting that these
substitutions did not disrupt metal binding (data not shown).
|
|
|
|
Substitutions to Residues Next to Putative Zinc Ligands.
Substitutions to residues next to each of the five putative zinc
ligands were also targeted. These included Asp-379, Pro-388, Glu-424, Ser-454, and Tyr-552. The following results are shown in
Tables 3 and 4. 1) Conservative substitutions at Asp-379 resulted in no
detectable enzyme activity (after a 16-h incubation) and in a reduced
expression of protein, underscoring the importance of the structure in
this region. In the Streptomyces and
Vibrio aminopeptidases, the corresponding residue was
hydrogen bonded to the nearby histidine zinc ligand. 2) Substitution of
Pro-388 to Ala resulted in a large increase in
Km. It has been noted in binuclear zinc
metallopeptidases that a cis-peptide bond occurs near
one of the zinc ligands (Table 1). 3) The E424Q mutant resulted in a
reduced Vmax value along with an increase in
Km (Fig. 3 and Table 4). A glutamate
implicated in catalysis is typically found next to one of the zinc
ligands in both bi- and mononuclear zinc metallopeptidases (Rowsell et
al., 1997
). 4) The S454A mutant had a decrease in
Vmax. 5) The Y552F mutant had an increased
Km and decreased
Vmax. In the Vibrio and
Streptomyces aminopeptidases the corresponding positions
(Ser-454 and Tyr-552) are implicated as comprising part of the
substrate binding pocket indicating proximity to the active site.
Substitutions to Putative Substrate Ligands. In contrast to substitutions to putative zinc ligands, single substitutions to putative substrate ligands were less disruptive to enzyme activity so that kinetic parameters could be obtained for most of the mutants. For the positively charged residues implicated in determining substrate specificity, including Lys-500, conservative substitutions that exchanged Lys for Arg did not markedly alter the kinetic parameters (Table 4). However, when the substitution introduced a large charge perturbation (e.g., Lys to Glu), the Km for substrate of these mutants increased greatly. This was seen for the R463I, R536E, and K545E mutants (Table 4, an example of which is shown in Fig. 3A). Immunoblot analysis indicates that the expression of these mutants is like wild type except that the upper band is faint for the R463I mutant (data not shown). No activity was detected for the K500E mutant (after a 16-h incubation), and reduced expression was observed in an immunoblot (Fig. 2A). Little change in the kinetic parameters was seen for the K499E and S501A mutants, even though they are directly next to Lys-500, which has no activity when substituted to Glu. Very little activity was seen for the N519D mutant after a 16-h incubation, so kinetic parameters could not be obtained. Finally, the T538V mutant had a large increase in the Km parameter (Table 4). Residues corresponding to Asn-519 and Thr-538 have been implicated in contributing to the substrate binding pocket of the aminopeptidases.
Enzyme Activity in the Presence of Inhibitors.
To further
analyze mutants that may affect substrate binding,
[3H]NAAG hydrolysis was measured in the presence of
inhibitors or the unlabeled alternative substrate,
pteroylpenta-
-glutamate (Pinto et al., 1996
). The IC50
was determined for pteroylpenta-
-glutamate in the presence of
[3H]NAAG for some of the mutants (Table
5). An 8- and 9-fold increase was seen in
the IC50 for the R536E and K545E mutants, respectively (Table 5), consistent with their increased
Km for NAAG (Table 4). The Y552F mutant
showed dramatic changes in the IC50 for PMPA, phosphate,
glutamate, and pteroylpenta-
-glutamate (Table 6), suggesting a role for this residue in
binding these inhibitors and/or NAAG.
|
|
Immunoblot Analysis.
To determine whether mutant protein was
expressed, immunoblot analysis was performed. Mutant protein was
expressed even for those mutants that showed no activity (Fig. 2A). Two
bands observed in the immunoblot suggest that two different species
were present. One explanation for the two bands is differential
glycosylation. To test this, the lysate from cells transfected with
wild-type cDNA (i.e., expression of native enzyme) was deglycosylated
under denaturing conditions and run on a gel for immunoblot analysis. One band was predominately seen at 84 kDa, consistent with the predicted size of the GCP II polypeptide (i.e., deglycosylated protein)
(Fig. 2B). The human prostate cancer cell line LNCaP overexpresses GCP
II (Israeli et al., 1994
). The LNCaP cell lysates expressed one 7E11-C5
immunoreactive species that migrated at a position that is in between
the two bands from the transfected samples. Upon deglycosylation this
band migrated at the same position as the deglycosylated transfected
sample (Fig. 2B).
-glutamate (Table 5). In general, anomalous band
migration (e.g., D387L in Fig. 2A) in the immunoblot, indicated by
italics in Tables 3 and 4, correlated with no detectable activity, with
the exception of N459D. For those mutants for which kinetic parameters
were obtained, the two bands seen in the immunoblot migrated with
wild-type protein, suggesting that glycosylation had not drastically
changed and that the affect of the mutation was the result of the
substitution and not due to a change in glycosylation.
| |
Discussion |
|---|
|
|
|---|
Site-directed mutagenesis has been performed in the human gene for
GCP II to test assignments of specific amino acids implicated in metal
ligand binding, substrate binding, and other structural and functional
aspects of enzyme catalysis. Assignments of these residues are based on
the amino acid sequence alignment of GCP II to low molecular weight
aminopeptidases whose crystal structures have been determined (Chevrier
et al., 1994
; Rawlings and Barrett, 1997
; Greenblatt et al., 1997
).
These aminopeptidases from S. griseus and V. proteolyticus are cocatalytic zinc metallopeptidases that are
members of the peptidase family M28. Zinc ligands are conserved between
these aminopeptidases and GCP II (Table 1). However, putative substrate
ligands are not conserved (Table 2), consistent with a difference in
substrate specificity. All residues targeted for mutagenesis that
resulted in altered kinetic parameters, including putative substrate
ligands, are conserved among the human, rat, and pig.
Substitutions to Putative Zinc Ligands.
Single substitutions
have been designed at each of the five putative Zn++
ligands (Table 3). A topological diagram, based on the
Vibrio aminopeptidase structure, is shown in Fig.
4 summarizing the mutagenesis results and
indicating the corresponding ligands in GCP II. In general,
substitutions to putative zinc ligands are more disruptive to enzyme
activity and stability as detected by immunoblot analysis than are
substitutions to putative substrate ligands. It is not uncommon for
apo-proteins to be less stable than their holoenzyme. For example,
increased protease susceptibility was observed in the apo-enzyme of a
mutated zinc binding site of peptide deformylase from
Escherichia coli (Meinnel et al., 1995
).
|
Substitutions to Residues Next to Putative Zinc Ligands.
Amino
acid residues next to metal ligands can affect the local structure
and/or function of the enzyme. In the crystal structures of the
Streptomyces and Vibrio aminopeptidases,
the corresponding Asp-379 is shown to hydrogen bond to His-377. There
may be a requirement for the proper positioning or electronic
interaction of His-377 such that substitution of Asp-379 to Glu or Asn
dramatically perturbs the local structure and/or function (Table 3).
This triad feature (e.g., Asp-His-Zn++) is also found in
other proteases such as the mononuclear zinc site of thermolysin in
which both zinc-associated histidines are also coordinated by either an
Asn or Asp. It has been proposed that the active site of neutral
endopeptidase (NEP) has a similar structure to thermolysin (Benchetrit
et al., 1988
). A substitution similar to the present case in NEP also
decreased enzyme activity in which the corresponding Asp of the triad
(i.e., Asp-650) was mutated to Glu, Asn, or Ala, (Le Moual et al.,
1994
).
Putative Substrate-Binding Determinants.
Four positively
charged residues in GCP II have been predicted by Rawlings and Barrett
(1997)
to be involved in the binding of the negatively charged
substrates. The corresponding residues in the Vibrio
aminopeptidase make up part of the hydrophobic substrate specificity
pocket. The present data support the assignment of these specificity
determinants. Because many residues are involved in substrate binding,
it might be expected that any one residue would contribute only
partially to the overall affinity for substrate. In this case, a single
substitution would not be expected to eliminate binding. The data
support this concept, because certain substitutions alter but do not
abolish activity. Only when the substitution was a large charge
perturbation, such as Lys to Glu, has a large change in
Km been observed. The only prediction not
substantiated was for Lys-499. However, this amino acid is not
conserved in the rat or pig sequence (Bzdega et al., 1997
; Halsted et
al., 1998
; Luthi-Carter et al., 1998
). Interestingly, there is another Lys conserved in the rat and pig sequences directly next to Lys-499 at
position 500 wherein substitution to Glu resulted in a loss of enzyme
activity. Location of these putative substrate binding residues is
shown in Fig. 4. An exchange of Lys and Arg did not seem to perturb
substrate binding (Table 4), supporting the role of the positively
charged nature of these residues in binding. Altered binding of
pteroylpenta-
-glutamate by some of these mutants indicates that NAAG
and folylpolyglutamate may share common binding determinants. Our data
indicate that specific residues, including positively charged ones,
influence substrate binding either directly or indirectly and are
consistent with the model proposed by Rawlings and Barrett (1997)
.
Identification of Important Structural and Functional
Elements through Evolutionary Conservation.
Important structural
similarities are often identified by similarities between mammalian and
bacterial proteins. Interesting examples for which mutagenesis studies
have been conducted include both metabotropic and ionotropic glutamate
receptors, such as the N-methyl-D-aspartate
receptor in which similarities to bacterial amino acid binding proteins
have been observed (O'Hara et al., 1993
; Kuryatov et al., 1994
;
Stern-Bach et al., 1994
; Paas et al., 1996
). As mentioned previously,
structural similarities have been identified between NEP, a type II
membrane zinc metallopeptidase, and the mononuclear zinc containing
thermolysin (Benchetrit et al., 1988
). Mutagenesis analyses of NEP
support assignments made from the sequence alignment even though little
amino acid identity exists between the two sequences (Marie-Claire et
al., 1997
and references therein). These studies, like the current one,
suggest that the three-dimensional structure of the mammalian proteins are similar to their bacterial counterparts and that structural and
functional elements can be predicted based on these comparisons. Lastly, our data from the mutagenesis studies may provide useful information to aid in the design of pharmacologic reagents.
| |
Acknowledgments |
|---|
We thank Drs. Gerald Murphy and Alton Boynton for the monoclonal antibody 7E11-C5, Drs. Rudy Tanzi and Robert Moir for assistance in quantitating immunoblots, Dr. Craig Martin for discussion on kinetic analysis, and Drs. Neil Rawlings and Alan Barrett for review of the manuscript.
| |
Footnotes |
|---|
Received August 3, 1998; Accepted October 19, 1998
This work was supported by National Association for Research on Schizophrenia and Affective Disorders Hilton Senior Investigator Award (to J.T.C.), National Research Service Award fellowships from the National Institute of Mental Health 5-T32-MH14275-21 (to B.K. Madras), and 1 F32 MH11895-01 (to H.S.S.).
Send reprint requests to: Dr. Joseph Coyle, McLean Hospital, 115 Mill St., Belmont, MA 02178. E-mail: jcoyle{at}warren.med.harvard.edu
| |
Abbreviations |
|---|
GCP II, glutamate carboxypeptidase II; NAAG, N-acetyl-aspartylglutamate; NEP, neutral endopeptidase; PMPA, 2-(phosphonomethyl)pentanedioic acid.
| |
References |
|---|
|
|
|---|
-glutamate carboxypeptidase from pig jejunum: Molecular characterization and relation to glutamate carboxypeptidase II.
J Biol Chem
273:
20417-20424
-linked acidic dipeptidase.
J Med Chem
39:
619-622[Medline].
-linked acidic dipeptidase activity from rat brain.
J Biol Chem
262:
14498-14506
-linked-L-glutamate.
J Neurochem
55:
39-46[Medline].
-linked acidic dipeptidase (NAALADase).
J Comp Neurol
315:
217-229[Medline].This article has been cited by other articles:
![]() |
H. Unno, T. Yamashita, S. Ujita, N. Okumura, H. Otani, A. Okumura, K. Nagai, and M. Kusunoki Structural Basis for Substrate Recognition and Hydrolysis by Mouse Carnosinase CN2 J. Biol. Chem., October 3, 2008; 283(40): 27289 - 27299. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. I. Davis, M. J. Bennett, L. M. Thomas, and P. J. Bjorkman Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase PNAS, April 26, 2005; 102(17): 5981 - 5986. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Ghosh, X. Wang, E. Klein, and W. D.W. Heston Novel Role of Prostate-Specific Membrane Antigen in Suppressing Prostate Cancer Invasiveness Cancer Res., February 1, 2005; 65(3): 727 - 731. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. A. Rajasekaran, G. Anilkumar, E. Oshima, J. U. Bowie, H. Liu, W. Heston, N. H. Bander, and A. K. Rajasekaran A Novel Cytoplasmic Tail MXXXL Motif Mediates the Internalization of Prostate-specific Membrane Antigen Mol. Biol. Cell, December 1, 2003; 14(12): 4835 - 4845. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Schulke, O. A. Varlamova, G. P. Donovan, D. Ma, J. P Gardner, D. M. Morrissey, R. R. Arrigale, C. Zhan, A. J. Chodera, K. G. Surowitz, et al. The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy PNAS, October 28, 2003; 100(22): 12590 - 12595. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Devlin, E.-h. Ling, J. M. Peerson, S. Fernando, R. Clarke, A. D. Smith, and C. H. Halsted Glutamate carboxypeptidase II: a polymorphism associated with lower levels of serum folate and hyperhomocysteinemia Hum. Mol. Genet., November 1, 2000; 9(19): 2837 - 2844. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||